Seed funding from Redesign Health fuels U.S. expansion and broadens access to clinical and multi-omics data from Asia, bringing greater diversity to drug development and healthcare AI.

来自Redesign Health的种子资金推动了其在美国的扩张，并拓宽了从亚洲获取临床和多组学数据的渠道，为药物开发和医疗人工智能带来了更大的多样性。

SAN FRANCISCO

旧金山

,

，

Aug. 25, 2026

2026年8月25日

/PRNewswire/ -- OmicsBank, a clinical data infrastructure company connecting fragmented hospital data for drug development and healthcare AI, today announced $2.25 million in seed funding from global venture capital and technology firm Redesign Health. The investment will support U.S. expansion across health systems, pharmaceutical and biotechnology companies, CROs, and AI developers, while growing its clinical data network across Asia and the Middle East..

/美通社/ -- OmicsBank 是一家临床数据基础设施公司，致力于连接分散的医院数据以支持药物研发和医疗人工智能。该公司今日宣布获得来自全球风险投资与科技企业 Redesign Health 的 225 万美元种子轮融资。这笔投资将支持其在美国面向医疗系统、制药和生物技术公司、合同研究组织（CRO）以及人工智能开发商的业务扩张，同时推动其临床数据网络在亚洲和中东地区的增长。

Global drug development and healthcare AI rely heavily on clinical and genomic datasets from the U.S. and Europe, leaving some of the world's largest populations significantly underrepresented in the evidence used to develop drugs, identify biomarkers, and train medical AI. India alone accounts for nearly 20% of the world's population, and South Asian countries represent nearly 25% of the world's population, yet they account for approximately .

全球药物研发和医疗保健人工智能高度依赖来自美国和欧洲的临床与基因组数据集，导致在用于药物开发、生物标志物识别以及医疗人工智能训练的证据中，世界上一些最大规模的人群代表性严重不足。仅印度一国就占世界人口的近20%，南亚国家合计占世界人口的近25%，然而它们所占的比例约为。

2% or less of participants

不超过2%的参与者

in large-scale global genomic research.

在大规模全球基因组研究中。

OmicsBank is building the infrastructure to close that gap. Founded in 2025 by Sumit Sinha and Vijay Goel, the company's technology now sits inside more than 90 hospitals and diagnostic labs in Asia, standardizing and de-identifying multimodal data at the source. Its ecosystem currently includes longitudinal EHR data from 12.5 million patients, more than 30 million DICOM images, 6 million pathology slides, and 500,000 genome sequences..

OmicsBank 正在构建基础设施以弥合这一差距。该公司由 Sumit Sinha 和 Vijay Goel 于 2025 年创立，其技术目前已部署在亚洲 90 多家医院和诊断实验室中，在数据源头对多模态数据进行标准化和去标识化处理。其生态系统目前包含来自 1,250 万患者的纵向电子健康记录（EHR）数据、超过 3,000 万张 DICOM 影像、600 万张病理切片以及 50 万个基因组序列。

OmicsBank is already working with pharmaceutical and biotechnology companies on drug development and real-world evidence studies across oncology, neurology, cardiology, nephrology, endocrinology, immunology, and dermatology. The company is also working with frontier AI organizations on pre-training, post-training, and reinforcement learning (RL) for clinical and multimodal models..

OmicsBank 已与制药和生物技术公司合作，在肿瘤学、神经学、心脏病学、肾脏病学、内分泌学、免疫学和皮肤病学等领域开展药物开发和真实世界证据研究。该公司还与前沿人工智能组织合作，针对临床和多模态模型开展预训练、后训练以及强化学习（RL）工作。

'Drug development and healthcare AI are becoming increasingly sophisticated, but the data powering them still represents a relatively narrow slice of the world,' said Sumit Sinha, Co-Founder and CEO of OmicsBank. 'We've built the infrastructure to make rich clinical and biological data from Asia and other underrepresented populations available for research, ethically and at scale, while remaining compliant with local and international laws.

“药物研发和医疗人工智能正变得日益复杂精密，但驱动它们的数据仍然仅代表了世界相对狭窄的一部分，”OmicsBank 联合创始人兼首席执行官 Sumit Sinha 表示。“我们已构建起基础设施，以合乎伦理且具规模的方式，提供来自亚洲及其他代表性不足人群的丰富临床和生物数据用于研究，同时确保遵守当地和国际法律。”

As we expand beyond Asia, including the U.S., we see an opportunity to connect that global data foundation with leading health systems, drug developers, and AI companies to build a much richer picture of human health.'.

“随着我们向亚洲以外地区（包括美国）拓展，我们看到一个机会，可以将这一全球数据基础与领先的医疗系统、药物研发企业和人工智能公司连接起来，从而构建一幅更为丰富的人类健康图景。”

Representation is only part of the challenge. Hospital data remains fragmented across EHRs, labs, imaging, pathology, and other systems, making it difficult to build longitudinal patient records linking diagnoses, treatments, and outcomes. That fragmentation has also limited researchers' ability to tap the scale and diversity of clinical data across Asia, the US, and the EU..

数据表征只是挑战的一部分。医院数据在电子健康记录（EHR）、实验室、影像、病理及其他系统中仍然分散，使得难以构建连接诊断、治疗和结果的纵向患者记录。这种分散性也限制了研究人员利用亚洲、美国和欧盟临床数据的规模和多样性的能力。

OmicsBank standardizes and de-identifies that information within the hospital environment, linking clinical events with imaging and multi-omics data. For pharma, biotech, and frontier AI teams, that means diverse, research-ready multimodal data to study disease, biomarkers, and treatment response, and to train and evaluate models.

OmicsBank 在医院环境中对信息进行标准化和去标识化处理，将临床事件与影像及多组学数据相链接。对于制药、生物技术和前沿人工智能团队而言，这意味着可获得多样化、可用于研究的多模态数据，以研究疾病、生物标志物和治疗反应，并用于训练和评估模型。

For participating hospitals, it means tools to query their own clinical archives, identify research cohorts, and support prospective studies..

对于参与医院而言，这意味着拥有查询自身临床档案、识别研究队列以及支持前瞻性研究的工具。

In the U.S., OmicsBank is pursuing a two-sided expansion strategy: providing pharmaceutical, biotechnology, CRO, and frontier AI organizations with access to research-ready data from Asia, while partnering with U.S. health systems to build research-ready data infrastructure and bring additional populations into its standardized, longitudinal data network.

在美国，OmicsBank 正在推行双向扩张战略：一方面为制药、生物技术、合同研究组织（CRO）以及前沿人工智能机构提供来自亚洲的科研就绪数据；另一方面与美国医疗系统合作，构建科研就绪的数据基础设施，并将更多人群纳入其标准化、纵向数据网络。

Together, this creates opportunities for research across populations and geographies using multimodal, multi-omics data..

这共同为利用多模态、多组学数据开展跨人群和跨地域的研究创造了机遇。

'Healthcare innovation has become global, and we believe some of the companies with the greatest potential to impact U.S. healthcare will come from exceptional founders solving problems at global scale,' said Neil Patel, Head of Ventures at Redesign Health. 'With OmicsBank, we underwrote Sumit and Vijay first, and the market second.

Redesign Health 风投主管尼尔·帕特尔表示：“医疗创新已走向全球化，我们相信，一些最具潜力影响美国医疗保健体系的公司，将来自那些在全球范围内解决重大问题的杰出创始人。对于 OmicsBank，我们首先看好的是苏米特和维贾伊这两位创始人，其次才是市场。”

They saw early that the lack of well-structured, representative clinical data was becoming a constraint on drug development and research, and they moved quickly to do something about it. Between them, they have built five companies and know how to operate in exactly the conditions OmicsBank demands, where progress depends on earning the trust of hospitals one institution at a time.

他们很早就意识到，缺乏结构良好、具有代表性的临床数据正成为药物研发和研究的瓶颈，并迅速采取行动加以应对。他们联手创立了五家公司，深谙如何在OmicsBank所要求的条件下运营，即进展取决于逐一赢得各家医院的信任。

That combination of speed and operating judgment is rare, and it's what gave us the conviction to invest.'.

这种速度与运营判断力的结合实属罕见，也正是它坚定了我们投资的信心。

'Making medical and pharmaceutical research more representative of emerging-market populations is not only a matter of inclusion. People underrepresented in medical research make up the majority of the world's population. OmicsBank is building the infrastructure to make this data accessible and improve healthcare globally,' said Oscar Ramos Moreno, Managing General Partner at Orbit Ventures, who led OmicsBank's pre-seed round in 2025..

“让医药研究更具新兴市场经济体人口的代表性，不仅关乎包容性。在医学研究中代表性不足的人群构成了全球人口的多数。OmicsBank 正在建设基础设施，以使这些数据易于获取，并改善全球医疗保健水平。”Orbit Ventures 的管理普通合伙人奥斯卡·拉莫斯·莫雷诺表示，他于 2025 年主导了 OmicsBank 的预种子轮融资。

With the new funding, OmicsBank will expand its hospital network across the U.S., the Middle East, and Southeast Asia while growing relationships with pharmaceutical, biotechnology, and AI companies. The company is also developing GPU-enabled research environments for AI model training, reinforcement learning environments, biomarker discovery, real-world evidence, and other computational biology research..

凭借新获得的资金，OmicsBank 将扩大其在美国、中东和东南亚的医院网络，同时加强与制药、生物技术和人工智能公司的合作关系。该公司还在开发支持 GPU 的研究环境，用于人工智能模型训练、强化学习环境、生物标志物发现、真实世界证据以及其他计算生物学研究。

About OmicsBank

关于OmicsBank

OmicsBank is a clinical data infrastructure company. Its platform is deployed within hospital and diagnostic networks across South Asia, Southeast Asia, and the Middle East, turning fragmented, unstructured clinical records into standardized, de-identified, patient-level datasets that research and AI systems can query directly.

OmicsBank 是一家临床数据基础设施公司。其平台部署于南亚、东南亚和中东地区的医院及诊断网络中，将分散、非结构化的临床记录转化为标准化、去标识化的患者级数据集，供研究和人工智能系统直接查询。

Its offering spans FHIR, OMOP CDM-structured EHR data, imaging, and genomic, transcriptomic, proteomic, phenomic, and metabolomic datasets and biospecimens — all made available under IRB and ethics committee approval, through an ISO 27001-certified, HIPAA- and GDPR-compliant process. OmicsBank works with pharma companies and frontier AI labs on drug discovery, drug development, and clinical AI.

其提供的数据涵盖 FHIR 标准数据、基于 OMOP CDM 结构的电子健康记录（EHR）数据、医学影像，以及基因组学、转录组学、蛋白质组学、表型组学和代谢组学数据集与生物样本——所有数据均在机构审查委员会（IRB）和伦理委员会批准下，通过符合 ISO 27001 认证、HIPAA 和 GDPR 合规的流程提供。OmicsBank 与制药公司及前沿人工智能实验室合作，共同推进药物发现、药物开发和临床人工智能应用。

Backed by Redesign Health and Orbit Ventures, OmicsBank is headquartered in San Francisco, California. Learn more at .

OmicsBank 由 Redesign Health 和 Orbit Ventures 支持，总部位于加利福尼亚州旧金山。了解更多详情，请访问。

omicsbank.com

omicsbank.com

.

。

About Redesign Health

关于 Redesign Health

Redesign Health is a global venture and applied technology firm focused on building next-generation healthcare companies. We manage venture capital and venture buyout strategies, each powered by an AI operating system and team of leading technologists, entrepreneurs, and investors. Our venture capital strategy backs exceptional founders at the earliest stage—often before an idea is fully formed—and provides first institutional capital and an unmatched degree of strategic leverage and domain expertise through exit.

Redesign Health 是一家全球性的风险投资与应用技术公司，专注于打造下一代医疗健康企业。我们管理着风险投资和风险收购策略，每项策略均由人工智能操作系统以及由顶尖技术专家、企业家和投资者组成的团队驱动。我们的风险投资策略在最早阶段支持杰出的创始人——往往在创意尚未完全成型时便介入——并提供首轮机构资本，以及从早期到退出阶段无与伦比的战略杠杆作用和领域专业知识。

Our venture buyout strategy partners with proven management teams through control investments and delivers outsized value by rewiring core products and workflows with AI. Since inception in 2018, Redesign and our portfolio companies have touched the lives of more than 15 million patients, raised over $1.5 billion from premier institutional, sovereign, and strategic investors, and built distinctive partnerships with marquee healthcare organizations and senior leaders around the world.

我们的风险收购策略通过控股投资与经验丰富的管理团队携手合作，并利用人工智能重塑核心产品和工作流程，从而创造超额价值。自2018年成立以来，Redesign 及其投资组合公司已惠及超过1,500万患者，从顶级机构投资者、主权财富基金和战略投资者处筹集超过15亿美元，并与全球知名的医疗保健机构及高层领导者建立了独特的合作伙伴关系。

Redesign is based in New York and has offices in Bengaluru, Los Angeles, and Riyadh. For more information, visit .

Redesign 总部位于纽约，并在班加罗尔、洛杉矶和利雅得设有办事处。欲了解更多信息，请访问。

www.redesignhealth.com

www.redesignhealth.com

Media Contact:

媒体联系人：

OmicsBank:

OmicsBank：

[email protected]

[email protected]

Redesign Health:

重新设计健康：

[email protected]

[email protected]

SOURCE Redesign Health; OmicsBank

来源：Redesign Health；OmicsBank

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示